drugset / Trial / NCT01378741
Reducing Delirium After Cardiac Surgery: A Multifaceted Approach Of Perioperative Care
Completed
185 enrolled
University Health Network, Toronto
Hospira, now a wholly owned subsidiary of Pfizer · collab
RandomizedSingle-groupSingle-blindPrevention
Summary
The objective of this study is to reduce the incidence of postoperative delirium after cardiac surgery in the elderly patient. This proposal is a clinical trial designed to reduce delirium in patients undergoing cardiac surgery by replacing standard postoperative sedation protocols (propofol, midazolam, opioids) with a new alpha2-adrenergic receptor agonist (dexmedetomidine) possessing sedative, analgesic, and antinociceptive properties. Resource utilization analysis will be performed to determine cost effectiveness of the new treatment modality.
Timeline
- Start
- 2011-04
- Primary completion
- 2014-07
- Completion
- 2015-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dexmedetomidine | Other / unclassified | 0.2 ug/kg | — |
| Comparator | Dexmedetomidine | Other / unclassified | 0.7 ug/kg | — |
| Comparator | Propofol | Small molecule | 2 mg/kg | — |
| Comparator | Propofol | Small molecule | 6 mg/kg | — |